14th European and Global CLINAM Summit
The 14th European and Global CLINAM-Summit will take place from October 8 to October 11, 2023, in Basel/Switzerland: "Crossing the Horizon towards novel Possibilities, Existing and Evolving Products, Technologies, Research and Strategies for Global Health".
The non-profit European Foundation for Clinical Nanomedicine will have after two virtual Summits in 2020 & 2022 its 14th Summit as a hybrid event with personal attendance and live stream.
CLINAM 14 /2023 will be the unique traditional platform with a scientific programme that will elucidate the state of the art of Nanomedicine in Production, Development and at Clinic for Prevention, Diagnosis and Therapy. In particular, since the development of mRNA vaccines based on lipid nanoparticles (LNPs), nanomedicine has received huge awareness and has matured by now to a boosting field with highest recognition. This is the right moment to review the development of the technology as well as looking at the products and their use in clinical medicine to the benefit of patients. The achievement of the revolutionary protective wall against COVID -19 by mRNA vaccines predicts a profound acceleration of innovative drug development to the benefit of patients.
However not for all humankind: A strong focus shall be, to enable and improve health care in countries where therapy until today is unaffordable or absent. Further, the delivery of drugs by different nanoparticles shall be an important issue. All stakeholders in the field, including many high-ranking scientists, Nobel Laureates and leading managers and regulatory authorities from all continents exploit the CLINAM-summit since 15 years for new projects and making bonds for cooperation. They all contribute to an excellent scientific outlook.
For 2023, CLINAM addressed three outstanding organizers of excellent conferences and invited them to participate with a session within the CLINAM-Summit. The different skills of the parties will give a great unique interdisciplinary perspective on nanomedicine and related fields in Europe
and on international level.
These organisations are:
Scientific Committee of the Summit 2023
- Prof. Dr. med. Patrick Hunziker, University Hospital Basel (CH)
- Prof. Dr. Lajos Balogh, Editor-in-Chief, Precision Nanomedicine, Boston (USA)
- Prof. Dr. Yechezkel Barenholz, Professor Emeritus, Head of Membrane and Liposome Research Lab, Hebrew University Hadassah Medical School, Jerusalem (IL)
- Prof. Dr. Dr. Twan Lammers, Institute for Experimental Molecular Imaging, RWTH Aachen (DE)
- Prof. Dr. med. Dong Soo Lee, Ph.D. Chairman, Department of Nuclear Medicine Seoul National University, Seoul (KOR)
- Dr. med. h.c. Beat Löffler, MA, CEO, CLINAM Foundation, Basel (CH)
- Prof. Dr. Gert Storm, Institute for Pharmaceutical Sciences, Utrecht University, Utrecht (NL)
- Prof. Dr. Dr. h.c. Viola Vogel, Head of the Laboratory of Applied Mechanobiology, Department for Health Sciences and Technology (HEST), ETH, Zürich (CH)
- PD Dr. Peter van Hoogevest, Member of the Scientific Advisory Council, Phospholipid Research Center, Heidelberg (DE)
- Prof. Dr. med. Raymond Schiffelers, Professor of Nanomedicine; Division LAB CDL Research; UMC Utrecht, Chairman of the ETP Nanomedicine Executive Board, Utrecht (NL)
- PD Dr. habil. Simon Drescher, Managing Director, Phospholipid Research Center, Heidelberg (DE)
- Prof. Dr. Theresa Allen, University of Alberta, University of British Columbia and Organizer of the Lipid Research Days 2022, Vancouver (CAN)
- Prof. Dr. Pieter Cullis, Professor of Biochemistry, University of B.C. (UBC) Vancouver, Cofounder of Acuitas Therapeutics, lipid nanoparticle technology, Vancouver (CAN)
- Dr. Martin Bornhöft, Head of the International Association for Pharmaceutical Technology (APV), Mainz (DE)
Format of the Meeting
The Summit will take place on the Novartis Campus in Basel, which is now also open to the public. The summit shall have on two days plenary sessions and will take place in the largest auditorium, which is located in the impressive building designed by Frank Gehry. The third day is in two halls dedicated to short statements to relevant fields with ample time to discuss and come to conclusions.
The exhibition and Poster Presentations as well as the lunches will be in the Foyer of the halls. The CLINAM Team will organize the meeting with as little as possible hurdles for the participants and is grateful for the support that Novartis gives.
The Phospholipid Research Center will organize a workshop during the CLINAM Summit.
The surprising role of monoacyl phospholipids (lysolipids) in drug delivery, medicine, and beyond.
Phospholipids are already included in numerous approved drug products, but their potential is far from exhausted: Phospholipids are extremely well tolerated, and their capabilities go far beyond those of conventional emulsifiers or solubilizers. The two vaccines against COVID-19 based on lipid nanoparticles (LNPs) are a striking example in this respect. When we talk about phospholipids, or more precisely diacyl phospholipids, we must always expect to find monoacyl phospholipids (MAPCs) as well. MAPCs, also known as lysolipids, differ from diacyl phospholipids in terms of their physicochemical characteristics, physiological role, and application. Therefore, despite having the negative reputation of being lytic to erythrocytes, this subgroup offers many positive properties.
The goal of this workshop is to introduce the audience to the characteristics of lysolipids, starting with their physicochemical properties, their role within cancer, their usefulness in stabilizing pharmaceutically used proteins, and ending with their applicability in various drug delivery systems.
- PD Dr. habil. Simon Drescher (PRC Heidelberg, Germany) - Introduction to the Phospholipid Research Center
- PD Dr. Peter van Hoogevest (PRC Heidelberg, Germany) - Phospholipids as nanomaterials
- Prof. Dr. Heiko Heerklotz (University of Freiburg, Germany) - The lysolipid paradox
- Prof. Dr. Ulrich Massing (University of Freiburg, Germany) - Stabilization of lyso-phosphatidylcholine-levels in patients with cancer
- Prof. Dr. Wolfgang Frieß (University of Munich, Germany) - Lyso phosphatidylcholine for the stabilization of pharmaceutical proteins against adsorption and aggregation
- Prof. Dr. Anette Müllertz (University of Copenhagen, Denmark) - Elucidating the use of lyso-phospholipids in oral self-nanoemulsifying drug delivery systems
- Prof. Dr. Martin Kuentz (University of Applied Sciences and Arts Northwestern Switzerland, Muttenz, Switzerland) - Lecithin and monoacyl lecithin as interacting excipients in oral bio-enabling formulations of poorly water-soluble drugs